Gilead Quad’s Side Effects Profile, Novel Agents To Get Advisory Committee Review
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Antiviral Drugs Advisory Committee takes up the four-drug HIV-1 regimen, which includes two new agents, on May 11. The firm hopes to be able to sell the combination in part on its favorable side effects profile if the product is approved.
You may also be interested in...
Medicines Patent Pool/BMS Deal On Atazanavir To Benefit 110 Developing Countries, But Not China And Brazil
The Medicines Patent Pool’s deal with BMS for licenses for the manufacture and supply of atazanavir for low- to middle-income countries will benefit up to a million HIV sufferers.
110 Countries Benefit From Medicines Patent Pool/BMS Deal On Atazanavir
The Medicines Patent Pool’s deal with BMS for licenses for the manufacture and supply of atazanavir for low- to middle-income countries will benefit up to a million HIV sufferers.
Profile Of Viiv’s Unboosted Dolutegravir Emerges With First Phase III Results
Viiv Healthcare/Shionogi’s once-daily, unboosted integrase inhibitor dolutegravir is efficacious and well-tolerated in the first of four Phase III HIV trials to report, a study of treatment-naïve patients. Drug poses a competitive threat to Merck’s blockbuster Isentress and Gilead’s elvitegravir, part of the four-in-one “Quad” pill.